Megadose (90)Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma

Allogeneic hematopoietic cell transplantation (allo-HCT) can be curative for relapsed or refractory B-cell lymphomas (BCLs), although outcomes are worse in aggressive disease, and most patients will still experience relapse. Radioimmunotherapy using (90)Y-ibritumomab tiuxetan can induce disease cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Chow, Victor A., Cassaday, Ryan D., Gooley, Theodore A., Smith, Stephen D., Sandmaier, Brenda M., Green, Damian J., Orozco, Johnnie J., Tuazon, Sherilyn A., Matesan, Manuela, Fisher, Darrell R., Maloney, David G., Press, Oliver W., Gopal, Ajay K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753215/
https://www.ncbi.nlm.nih.gov/pubmed/34649272
http://dx.doi.org/10.1182/bloodadvances.2021005056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753215/
https://www.ncbi.nlm.nih.gov/pubmed/34649272
http://dx.doi.org/10.1182/bloodadvances.2021005056

Ejemplares similares